
|Articles|November 25, 2020
Supplements and Featured Publications
- Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double-Blind, Multicentre, Randomised, Phase 2 Study
Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double-Blind, Multicentre, Randomised, Phase 2 Study
Advertisement
This publication was sponsored by Debiopharm International SA.
This Clinical Brief explores the double-blind, multicentre, randomised phase 2 study (NCT02022098) of Debio 1143 and high-dose cisplatin chemoradiotherapy in patients with high-risk locoregionally advanced squamous cell carcinoma of the head and neck.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Guideline-Directed Medical Therapies in Heart Failure
2
Responsible Use of Energy-Based Treatments on Skin of Color: Eliot F. Battle, MD
3
Collaboration in Heart Failure Treatment
4
Coordinating Medications for Women With Arrhythmia: Lindsey Valenzuela, PharmD
5